These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Pharmacological characterization of the novel γ-secretase modulator AS2715348, a potential therapy for Alzheimer's disease, in rodents and nonhuman primates. Mitani Y; Akashiba H; Saita K; Yarimizu J; Uchino H; Okabe M; Asai M; Yamasaki S; Nozawa T; Ishikawa N; Shitaka Y; Ni K; Matsuoka N Neuropharmacology; 2014 Apr; 79():412-9. PubMed ID: 24373902 [TBL] [Abstract][Full Text] [Related]
6. Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice. Rogers K; Felsenstein KM; Hrdlicka L; Tu Z; Albayya F; Lee W; Hopp S; Miller MJ; Spaulding D; Yang Z; Hodgdon H; Nolan S; Wen M; Costa D; Blain JF; Freeman E; De Strooper B; Vulsteke V; Scrocchi L; Zetterberg H; Portelius E; Hutter-Paier B; Havas D; Ahlijanian M; Flood D; Leventhal L; Shapiro G; Patzke H; Chesworth R; Koenig G Mol Neurodegener; 2012 Dec; 7():61. PubMed ID: 23249765 [TBL] [Abstract][Full Text] [Related]
7. Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer's disease. Blain JF; Bursavich MG; Freeman EA; Hrdlicka LA; Hodgdon HE; Chen T; Costa DE; Harrison BA; Kapadnis S; Murphy DA; Nolan S; Tu Z; Tang C; Burnett DA; Patzke H; Koenig G Alzheimers Res Ther; 2016 Aug; 8(1):34. PubMed ID: 27572246 [TBL] [Abstract][Full Text] [Related]
8. BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease. Scannevin RH; Chollate S; Brennan MS; Snodgrass-Belt PA; Peng H; Xu L; Jung MY; Bussiere T; Arastu MF; Talreja T; Xin Z; Dunstan RW; Fahrer D; Rohde E; Dunah AW; Wang J; Kumaravel G; Taveras AG; Moore Arnold H; Rhodes KJ Neuropharmacology; 2016 Apr; 103():57-68. PubMed ID: 26690893 [TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of an aminopiperidine series of γ-secretase modulators. Kobayashi T; Iwama S; Fusano A; Kato Y; Ikeda A; Teranishi Y; Nishihara A; Tobe M Bioorg Med Chem Lett; 2014 Jan; 24(1):378-81. PubMed ID: 24269163 [TBL] [Abstract][Full Text] [Related]
10. Pharmacological and Toxicological Properties of the Potent Oral Wagner SL; Rynearson KD; Duddy SK; Zhang C; Nguyen PD; Becker A; Vo U; Masliah D; Monte L; Klee JB; Echmalian CM; Xia W; Quinti L; Johnson G; Lin JH; Kim DY; Mobley WC; Rissman RA; Tanzi RE J Pharmacol Exp Ther; 2017 Jul; 362(1):31-44. PubMed ID: 28416568 [TBL] [Abstract][Full Text] [Related]
11. Dynamics of Aβ42 reduction in plasma, CSF and brain of rats treated with the γ-secretase modulator, GSM-10h. Hawkins J; Harrison DC; Ahmed S; Davis RP; Chapman T; Marshall I; Smith B; Mead TL; Medhurst A; Giblin GM; Hall A; Gonzalez MI; Richardson J; Hussain I Neurodegener Dis; 2011; 8(6):455-64. PubMed ID: 21389687 [TBL] [Abstract][Full Text] [Related]
12. Discovery of 2-methylpyridine-based biaryl amides as γ-secretase modulators for the treatment of Alzheimer's disease. Chen JJ; Qian W; Biswas K; Yuan C; Amegadzie A; Liu Q; Nixey T; Zhu J; Ncube M; Rzasa RM; Chavez F; Chen N; DeMorin F; Rumfelt S; Tegley CM; Allen JR; Hitchcock S; Hungate R; Bartberger MD; Zalameda L; Liu Y; McCarter JD; Zhang J; Zhu L; Babu-Khan S; Luo Y; Bradley J; Wen PH; Reid DL; Koegler F; Dean C; Hickman D; Correll TL; Williamson T; Wood S Bioorg Med Chem Lett; 2013 Dec; 23(23):6447-54. PubMed ID: 24139583 [TBL] [Abstract][Full Text] [Related]
16. γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Imbimbo BP; Giardina GA Curr Top Med Chem; 2011; 11(12):1555-70. PubMed ID: 21510832 [TBL] [Abstract][Full Text] [Related]
17. Selective modulation of Abeta42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond. Leuchtenberger S; Beher D; Weggen S Curr Pharm Des; 2006; 12(33):4337-55. PubMed ID: 17105431 [TBL] [Abstract][Full Text] [Related]
18. APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment. Sjödin S; Andersson KK; Mercken M; Zetterberg H; Borghys H; Blennow K; Portelius E Alzheimers Res Ther; 2015 Dec; 7(1):77. PubMed ID: 26689589 [TBL] [Abstract][Full Text] [Related]
19. Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds. Czirr E; Weggen S Neurodegener Dis; 2006; 3(4-5):298-304. PubMed ID: 17047371 [TBL] [Abstract][Full Text] [Related]
20. Chemical Biology, Molecular Mechanism and Clinical Perspective of γ-Secretase Modulators in Alzheimer's Disease. Bulic B; Ness J; Hahn S; Rennhack A; Jumpertz T; Weggen S Curr Neuropharmacol; 2011 Dec; 9(4):598-622. PubMed ID: 22798753 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]